Parkinson's disease (PD) & Movement disorders (MD)

Print
Section Heads: Joaquim Ferreira, Portugal & Heinz Reichmann, Germany
Please see below the CONy Scientific Program. Please click on the appropriate section to view the relevant program. Please note that the program and timng is subject to change. To view the program timetable / overview, please click here
 
For the full Scientific Program, please click here >
FRIDAY, MARCH 18, 2016
15:00-17:00
SYNUCLEIN DEMENTIAS
Chairs: Horacio Firmino, Portugal; Lev Kruglov, Russia
15:00-16:00 Debate: Is MCI-PD a useful concept?
Capsule: Each PD patient that lives long enough will develop dementia. It is intriguing to speculate whether early treatments may postpone the time for entering into nursing home. New treatment may also be used before the advent of dementia. For this reason it is important to define the early stages of dementia, which may be mild cognitive impairment (MCI). But is MCI-PD a useful concept?
15:00-15:10 Host: Laura Parkkinen, UK
15:10-15:25 Yes: Jaime Kulisevsky, Spain
15:25-15:40 No: Amos D. Korczyn, Israel
15:40-16:00 Discussion and rebuttals
16:00-17:00 Debate: Dementia with Lewy bodies and PD dementia: Part of one continuum or two distinct entities?
Capsule: Patients suffering from PD will develop dementia if they live long enough. In some cases, synuclein deposition in the cortex causes cognitive changes before the occurrence of parkinsonism. Are these two different disorders or two presentations of the same disorder?
16:00-16:25 Host: Lefkos T. Middleton, UK
16:10-16:25 Continuum: Laura Parkkinen, UK
16:25-16:40 Distinct entities: Robert Perneczky, UK
16:40-17:00 DIscussion and rebuttals
SATURDAY, MARCH 19, 2016
08:30-10:20
NEW DEVELOPMENTS IN TREATMENT AND PATHOGENSIS OF PD
Chairs: Tatyana Slobodin, Ukraine; Joaquim Ferreira, Portugal
08:30-09:25 Debate: Is the improvement of MAO-B-inhibitors clinically relevant?
Capsule: In contrast to L-Dopa and dopamine agonists, MAO-B-inhibitors seem to be less potent. On the other hand they improve patients with wearing-off and they also reduce off-time and increase on-time. In some instances they may cause dyskinesias which can be reduced by L-Dopa dose adjustment
08:30-08:40 Host: Heinz Reichmann, Germany
08:40-08:55 Yes: Laszlo Vecsei, Hungary
08:55-09:10 No: Spiros Konitsiotis, Greece
09:10-09:25 Discussion and rebuttals
09:25-10:20 Debate: Should PD patients with pre-existing imuplsive-compulsive behavior (ICB)'s be actively selected for dopamine agonist treatments?
09:25-09:35 Host: Heinz Reichmann, Germany
09:35-09:50 Yes: Per Odin, Germany
09:50-10:05 No: Angel Sesar, Spain
10:05-10:20 Discussion and rebuttals
10:35-12:25 REEVALUATION OF MODERN AND OLDER TREATMENTS: THE PROS AND CONS
Chairs: Jagdish Sharma, UK; Mário Miguel Rosa, Portugal
10:35-11:30 Proposition: Therapies targeting alpha-synuclein will be the treatment of choice in PD
Capsule: Since PD may be an alpha-synuclein spreading disease it may be beneficial to stop the propagation of alpha-synuclein by vaccination
10;35-10:45 Host: Heinz Reichmann, Germany
10:45-11:00 Yes: Dieter H. Meier, USA
11:00-11:15 No: Ruggero G. Fariello, Italy
11:15-11:30 Discussion and rebuttals
11:30-12:25 Debate: Prion-like spreading is a relevant theory for neurdegenerative diseases
Capsule: Several neurodegenerative diseases progress in a distinct anatomical pattern with identified starting points and spread. It has recently been suggested that this is caused by a spread of the pathology in a prion-like mechanism. If correct, this theory is important for the development of disease modifying therapies. Has the prion hypothesis been proven for PD?
11:30-11:40 Host: George Perry, USA
11:40-11:55 Yes: C. Warren Olanow, USA
11:55-12:10 No: Amos D. Korczyn, Israel
12:10-12:25 Discussion and rebuttals
15:00-17:00
IS WHAT WE HAVE ALWAYS WHAT WE NEED IN PD TREATMENT AND EVALUATION?
Chairs: Joao Massano, Portugal; Angel Sesar, Spain
15:00-16:00 Debate: Do COMT inhibitors have a future?
Capsule: COMT-inhibitors may come under pressure due to MAO-B-inhibitors and especially safinamide. Thus, it has to be discussed which patients should still receive COMT inhibitors as first line treatment in PD patients with mild dyskinesia and wearing-off
15:00-15:10 Host: Alfonso Fasano, Canada
15:00-15:25 Yes: Joaquim Ferreira, Portugal
15:25-15:40 No: Ubaldo Bonuccelli, Italy
15:40-16:00 Discussion and rebuttals
16:00-17:00 Debate: Duodopa vs. Apomorphine pumps vs. DBS in advanced PD
Capsile: Patients with advanced PD need invasive therapy, but which of the three options is the best choice under which circumstances?
16:00-16:10 Duodopa: Per Odin, Germany
16:10-16:25 Apomorphine pumps: Fabrizio Stocchi, Italy
16:25-16:40 DBS: Ovidiu Bajenaru, Romania
16:40-17:00 Discussion and rebuttals
PD/MD & NEUROPATHOLOGY
Chair:s Marco Onofrj, Italy; Joaquim Ferreira, Portugal
17:15-18:00 Debate: Ultrasound brain lesioning for the treatment of movement disorders?
Capsule: The widespread use of intracerebral electric stimulation is now widely used in advanced PD and other movement disorders, with low morbidity. Recently, brain lesioning with ultrasound has been shown to be effective and does not need anesthesia or craniotomy. Will this method become popular?
17:15-17:25 Host: Martin Rabey, Isarel
17:25-17:40 Yes: Jose Obeso, Spain
17:40-18:55 No: Néstor Gálvez-Jiménez, USA
18:55-19:00 Discussion and rebuttals
LECTURE SERIES
Chair: TBA
09:00-09:20 Trophic factors in PD are really useful tools
Martin Rabey, Israel
SUNDAY, MARCH 20, 2016
 
PLENARY LECTURES: BEYOND THE HORIZON SERIES
Chairs: Amélia Nogueria Pinto, Portugal; Sadagat Huseynova, Azerbaijan
12:00-12:30 Beyond the horizon in Huntingon's disease
Cristina Sampaio, USA
12:30-13:00 Challenges and unmet needs in PD
Jose Obeso, Spain